Research programme: phosphodiesterase 10A inhibitors - Amgen/Memory Pharmaceuticals

Drug Profile

Research programme: phosphodiesterase 10A inhibitors - Amgen/Memory Pharmaceuticals

Alternative Names: Phosphodiesterase 10 inhibitors - Amgen/Memory

Latest Information Update: 12 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Memory Pharmaceuticals
  • Developer Amgen; Memory Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Phosphodiesterase 10A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Neurological disorders; Psychiatric disorders

Most Recent Events

  • 12 Mar 2008 Memory Pharmaceuticals amends its collaboration agreement with Amgen regarding this programme
  • 17 Oct 2005 Preclinical trials in Neurological disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top